1Lewin KJ, Riddell RH, Weinstein WM, et al .Gastrointestinal pathology and its clinical implications. 1st ed. New York: Igaku-shoin. 1992,284-341.
2Nakahara M, Isozaki K, Hirota S, et al. A novel gain of function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology, 1998,115:1090-1095.
3Yarden Y, Kuang WJ, Yang-Feng T, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 1987,6:3341-3351.
4Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res, 1999,59:4297-4300.
5Moskaluk CA, Tian Q, Marshall CR ,et al. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene, 1999,18:1897-1902.
6Lasota J, Jasinski M, Sarlomo-Rikala M, et al. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointesinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol, 1999,154:53-60.
8Salomo Rikala M, Kovatich AJ, Barusevcius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol, 1998,11:728-734.
9Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998,279:577-580.
